Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis
出版年份 2020 全文链接
标题
Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis
作者
关键词
-
出版物
World Journal of Gastrointestinal Oncology
Volume 12, Issue 11, Pages 1346-1363
出版商
Baishideng Publishing Group Inc.
发表日期
2020-11-11
DOI
10.4251/wjgo.v12.i11.1346
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
- (2019) Xianjie Jiang et al. Molecular Cancer
- Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial
- (2019) Hyun Cheol Chung et al. Journal for ImmunoTherapy of Cancer
- Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
- (2019) Yung-Jue Bang et al. Gastric Cancer
- Recent advances in gastric cancer early diagnosis
- (2019) Laura Necula et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Camrelizumab: First Global Approval
- (2019) Anthony Markham et al. DRUGS
- Review: Gastric cancer—Clinical aspects
- (2019) Marino Venerito et al. HELICOBACTER
- Combination therapy with PD-1 or PD-L1 inhibitors for cancer
- (2019) Hidetoshi Hayashi et al. International Journal of Clinical Oncology
- Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
- (2019) Roy S Herbst et al. LANCET ONCOLOGY
- Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
- (2019) Ronan J. Kelly et al. CLINICAL CANCER RESEARCH
- A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
- (2019) Li-Tzong Chen et al. Gastric Cancer
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
- (2018) Kohei Shitara et al. LANCET
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
- (2018) Y -J Bang et al. ANNALS OF ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy
- (2018) Fatemeh K. Dermani et al. JOURNAL OF CELLULAR PHYSIOLOGY
- CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
- (2018) Yelena Y. Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1
- (2018) Lola Fashoyin‐Aje et al. ONCOLOGIST
- Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
- (2018) N Boku et al. ANNALS OF ONCOLOGY
- Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial
- (2018) Toshihiko Doi et al. Gastric Cancer
- Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus
- (2018) Manish A. Shah et al. JAMA Oncology
- Global patterns and trends in stomach cancer incidence: Age, period and birth cohort analysis
- (2017) Ganfeng Luo et al. INTERNATIONAL JOURNAL OF CANCER
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Yoon-Koo Kang et al. LANCET
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
- (2017) Florie Bertrand et al. Nature Communications
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- Gastroesophageal Cancers: Progress and Problems
- (2017) Jaffer A. Ajani Journal of the National Comprehensive Cancer Network
- PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis
- (2017) Lihu Gu et al. PLoS One
- Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability
- (2016) Changqing Ma et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) E. C. Smyth et al. ANNALS OF ONCOLOGY
- Management of toxicities of immune checkpoint inhibitors
- (2016) Lavinia Spain et al. CANCER TREATMENT REVIEWS
- Microsatellite Instability as a Biomarker for PD-1 Blockade
- (2016) J. C. Dudley et al. CLINICAL CANCER RESEARCH
- Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology
- (2016) Jaffer A. Ajani et al. Journal of the National Comprehensive Cancer Network
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
- (2016) Kei Muro et al. LANCET ONCOLOGY
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- PD-1 and its ligands are important immune checkpoints in cancer
- (2016) Yinan Dong et al. Oncotarget
- The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients
- (2016) Minghui Zhang et al. Scientific Reports
- Novel targets in the treatment of advanced gastric cancer: a perspective review
- (2016) Elisa Fontana et al. Therapeutic Advances in Medical Oncology
- Immunotherapy for Gastroesophageal Cancer
- (2016) Emily Goode et al. Journal of Clinical Medicine
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological features
- (2015) Yves Dittmar World Journal of Gastrointestinal Oncology
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Clinical epidemiology of gastric cancer
- (2014) TL Ang et al. SINGAPORE MEDICAL JOURNAL
- Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
- (2013) Hugo E R Ford et al. LANCET ONCOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
- (2010) David Moher et al. International Journal of Surgery
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation